Hoppensteadt D - Search Results

1

Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.

Fareed J, Hoppensteadt D, Walenga J, Iqbal O, Ma Q, Jeske W, Sheikh T. Fareed J, et al. Among authors: hoppensteadt d. Clin Pharmacokinet. 2003;42(12):1043-57. doi: 10.2165/00003088-200342120-00003. Clin Pharmacokinet. 2003. PMID: 12959635 Review.

2

Reduction of plasma levels of prothrombin fragments 1 and 2 during thromboprophylaxis with a low-molecular-weight heparin.

Sørensen JV, Lassen MR, Borris LC, Rahr HB, Jensen HP, Hoppensteadt D, Walenga JA, Fareed J. Sørensen JV, et al. Among authors: hoppensteadt d. Blood Coagul Fibrinolysis. 1992 Feb;3(1):55-9. doi: 10.1097/00001721-199202000-00009. Blood Coagul Fibrinolysis. 1992. PMID: 1320416 Clinical Trial.

3

Low molecular weight heparins. An objective overview.

Hoppensteadt D, Walenga JM, Fareed J. Hoppensteadt D, et al. Drugs Aging. 1992 Sep-Oct;2(5):406-22. doi: 10.2165/00002512-199202050-00005. Drugs Aging. 1992. PMID: 1327312 Review.

4

The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model.

Bacher P, Welzel D, Iqbal O, Hoppensteadt D, Callas D, Walenga JM, Fareed J. Bacher P, et al. Among authors: hoppensteadt d. Thromb Res. 1992 May 1;66(2-3):151-8. doi: 10.1016/0049-3848(92)90185-d. Thromb Res. 1992. PMID: 1329252

5

Hemostatic abnormalities in total artificial heart patients as detected by specific blood markers.

Walenga JM, Hoppensteadt D, Fareed J, Pifarré R. Walenga JM, et al. Among authors: hoppensteadt d. Ann Thorac Surg. 1992 May;53(5):844-50. doi: 10.1016/0003-4975(92)91448-i. Ann Thorac Surg. 1992. PMID: 1570981

6

Influence of recombinant hirudin and unfractionated heparin on thrombin and factor Xa generation in extrinsic and intrinsic activated systems.

Kaiser B, Fareed J, Hoppensteadt D, Birdsong B, Walenga JM, Markwardt F. Kaiser B, et al. Among authors: hoppensteadt d. Thromb Res. 1992 Jan 15;65(2):157-64. doi: 10.1016/0049-3848(92)90235-3. Thromb Res. 1992. PMID: 1579892

7

The effect of burn wound size on hemostasis: a correlation of the hemostatic changes to the clinical state.

Kowal-Vern A, Gamelli RL, Walenga JM, Hoppensteadt D, Sharp-Pucci M, Schumacher HR. Kowal-Vern A, et al. Among authors: hoppensteadt d. J Trauma. 1992 Jul;33(1):50-6; discussion 56-7. doi: 10.1097/00005373-199207000-00011. J Trauma. 1992. PMID: 1635106

8

Laboratory monitoring of the clinical effects of low molecular weight heparins.

Walenga JM, Hoppensteadt D, Fareed J. Walenga JM, et al. Among authors: hoppensteadt d. Thromb Res Suppl. 1991;14:49-62. doi: 10.1016/0049-3848(91)90403-j. Thromb Res Suppl. 1991. PMID: 1658970 Clinical Trial.

9

Experimental and clinical validation of the prophylactic antithrombotic effects of a low molecular weight heparin (enoxaparin).

Fareed J, Walenga JM, Hoppensteadt D, Borris LC, Lassen MR. Fareed J, et al. Among authors: hoppensteadt d. Semin Thromb Hemost. 1991;17 Suppl 3:319-28. Semin Thromb Hemost. 1991. PMID: 1661440 Review.

10

Comparative studies on various assays for the laboratory evaluation of r-hirudin.

Walenga JM, Hoppensteadt D, Koza M, Pifarre R, Fareed J. Walenga JM, et al. Among authors: hoppensteadt d. Semin Thromb Hemost. 1991 Apr;17(2):103-12. doi: 10.1055/s-2007-1002597. Semin Thromb Hemost. 1991. PMID: 1771408

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

398 results

Search Page

Filters